オビセトラピブとエゼチミブの定量併用によるLDLコレステロール低下 (TANDEM): ランダム化,ダブルブラインド,プラセボ対照試験
Ashish Sarraju1, Danielle Brennan1, Kierstyn Hayden1
1Department of Cardiovascular Medicine and Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH, USA.
Lancet (London, England)
|May 10, 2025
まとめ
オビセトラピブとエゼチミブの固定用量の組み合わせは,LDLコレステロールを著しく低下させた. この経口療法により,動脈硬化性心血管疾患 (ASCVD) の高リスクの患者におけるコレステロール管理の新たな選択肢が提供されます.
科学分野:
- 心血管医学
- 薬理学について
- 臨床試験
背景:
- LDLコレステロールの上昇は,動脈硬化性心血管疾患 (ASCVD) の主要な要因です.
- 効果的なLDLコレステロールの低下は,ASCVDの発生を予防するために不可欠です.
- 脂質管理を最適化するために新しい治療戦略が必要です.
研究 の 目的:
- オビセトラピブ (CETP阻害剤) とエゼチミブの固定用量併用によるLDLコレステロール低下の有効性を評価する.
- オビセトラピブまたはエゼチミブとプラセボによる単独治療に対するFDCの有効性を比較する.
主な方法:
- ランダム化され,ダブルブラインド試験で,ASCVDのリスクが高いまたはヘテロジゴス家族性高コレステロール症の407人の参加者が参加しました.
- 参加者は84日間,FDC (オビセトラピブ10 mg+エゼチミブ10 mg),オビセトラピブ10 mg単独治療,エゼチミブ10 mg単独治療,またはプラセボで毎日治療を受けました.
- コプライマリエンドポイントは,プラセボと単独治療の腕と比較して,LDLコレステロールの変化の割合に焦点を当てた.
主要な成果:
- プラセボと比較して-48. 6%の有意なLDLコレステロール低下を示した (p< 0. 001).
- エゼチミブ単独治療と比較して,FDCは-27. 9% (p< 0. 001) の減少を達成した.
- オビセトラピブ単独治療は,プラセボと比較してLDLコレステロールを31. 9%減少させた (p< 0. 001),すべての活性治療群で安全性プロファイルが類似した.
結論:
- オビセトラピブとエゼチミブの固定用量の組み合わせは,実質的なLDLコレステロール低下をもたらします.
- ASCVDの予防のための高脂血症の管理において,この単一の錠剤による経口療法は,潜在的に貴重な進歩を表しています.
- FDCは,より集中的なLDLコレステロール低下を必要とする患者に効果的な治療法を提供します.
関連する概念動画
Clinical Trials: Overview
2.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.6K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
492
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
492
Phase I Oxidative Reactions: Overview
220
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
220
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Drug Metabolism: Phase I Reactions
2.9K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
2.9K
Dosage Regimen: Fixed Dose
1.8K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.8K


